Mayo Clinic Laboratories > Renal > Urinary stone services

Urinary Stone Services

Quickly diagnose complex cases

Stone disease has a multifactorial etiology involving heredity, lifestyle, and dietary factors. Providing patients with recommendations for the prevention and control of kidney stone formation is integral to decreasing the prevalence of stones and their associated costs.1

To optimize patient care, our kidney stone services help identify metabolic and physical compositions. Our comprehensive approach and concise report enable accurate interpretation to guide clinical decisions.

1 in 11

1 in 11 people in the United States are affected by kidney stones at least once in their lifetime2

60%-80%

60%–80% of patients with stone events will have recurrent episodes later in life3

90,000

90,000 kidney stones analyzed annually at Mayo Clinic Laboratories

Kidney stones Kidney stones
KIDNEY STONES

Our kidney stone services identify the physical composition of stones. Our analysis utilizes Fourier transform infrared spectroscopy (FTIR), the accepted reference method to assess kidney stone composition.

Hereditary kidney stones Hereditary kidney stones
Hereditary kidney stones

Our nephrocalcinosis, nephrolithiasis, and renal electrolyte imbalance gene panel assesses 72 genes associated with inherited conditions that can lead to stone development. Mayo Clinic nephrologists and geneticists developed the panel. 

Urine supersaturation Urine supersaturation
Urine supersaturation

In patients for whom stone analysis is not available due to having a radiopaque stone, our kidney stone testing services can predict the likely composition of stones. This helps identify risk factors for stone development, design a treatment program, and monitor treatment effectivity.

References
  1. Goldfarb DS, Arowojolu O. Metabolic evaluation of first-time and recurrent stone formers. Urol Clin North Am. 2013 Feb;40(1):13–20.
  2. Scales CD Jr, Smith AC, Hanley JM, Saigal CS. Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160–165.
  3. Morton AR, Iliescu EA, Wilson JW. Nephrology: 1. Investigation and treatment of recurrent kidney stones. CMAJ. 2002 Jan 22;166(2):213-8. PMID: 11829004; PMCID: PMC99277
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.